Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs

mAbs

Volumn 7, Issue 2, 2015, Pages 344-351

  Roopenian, Derry C ^a   Low, Benjamin E ^a   Christianson, Gregory J ^a   Proetzel, Gabriele ^a   Sproule, Thomas J ^a   Wiles, Michael V ^a  

^a JACKSON LABORATORY   (United States)

Author keywords

Albumin; Albumin conjugates; Analbuminemia; Human serum albumin; Hypoalbuminemia; Mouse model; Neonatal Fc receptor; Pharmacokinetics; TALEN; Transgenic

Indexed keywords

FC RECEPTOR; HUMAN IMMUNOGLOBULIN; HUMAN SERUM ALBUMIN; SERUM ALBUMIN;

ANALBUMINEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CONTROL; CONTROLLED STUDY; DRUG METABOLISM; GENE DISRUPTION; HISTOPATHOLOGY; HUMAN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA HALF LIFE; ZYGOTE; ANIMAL; BIOLOGICAL MODEL; GENETICS; HALF LIFE TIME; KNOCKOUT MOUSE;

ANIMALS; HALF-LIFE; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; SERUM ALBUMIN;

EID: 84924619421     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1008345     Document Type: Article

References (42)

1. Peters T. All about Albumin: Biochemistry, Genetics, and Medical Applications. San Diego: Academic Press, 1995
2. Cameron JS. Milk or albumin? The history of proteinuria before Richard Bright. Nephrol Dial Transplant 2003; 18:1281-5; http://dx.doi.org/10.1093/ndt/ gfg130
3. Peters T Jr. Serum albumin. Adv Protein Chem 1985; 37:161-245; PMID:3904348; http://dx.doi.org/ 10.1016/S0065-3233(08)60065-0.
4. st century. Biochim Biophys Acta 2013; 1830:5351-3; http://dx.doi.org/10.1016/j.bbagen.2013.05.012
5. Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol Aspects Med 2012; 33:209-90; PMID:22230555; http://dx.doi.org/10.1016/j. mam.2011.12.002
6. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13:1-110; PMID:4186070
7. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol, 2000:739-66; PMID:10837074; http://dx.doi.org/10.1146/annurev.immunol.18.1.739
8. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: Distinct from the FcRn-IgG interaction. Biochemistry 2006; 45:4983-90; PMID:16605266; http://dx.doi.org/ 10.1021/bi052628y
9. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27:343-8; PMID:16731041; http://dx.doi.org/10.1016/j.it.2006.05.004
10. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/ nri2155
11. Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem 2014; 289:13492-502; PMID:24652290; http://dx.doi.org/10.1074/jbc. M114.549832
12. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS. Neonatal Fc receptor: From immunity to therapeutics. J Clin Immunol 2010; 30:777-89; PMID:20886282; http://dx.doi.org/ 10.1007/s10875-010-9468-4
13. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132:171-83; PMID:18582981; http://dx.doi. org/10.1016/j.jconrel.2008.05.010
14. Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs. Crit Rev Oncol Hematol 2013; 88:504-13; PMID:23871532; http://dx.doi.org/10.1016/j. critrevonc.2013.06.010
15. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 2013; 1830:5526-34; http://dx.doi.org/10.1016/j. bbagen.2013.04.023
16. Yamasaki K, Chuang VTG, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 2013; 1830:5435-43; http://dx. doi.org/10.1016/j.bbagen.2013.05.005
17. Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a spe-cies-dependent manner: Implications for in vivo halflife evaluation of albumin fusion therapeutics. J Biol Chem 2013; 288:24277-85; PMID:23818524; http:// dx.doi.org/10.1074/jbc.M113.463000
18. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285:4826-36; PMID:20018855; http:// dx.doi.org/10.1074/jbc.M109.081828
19. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/ dxl110
20. Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol, 2010:93-104; PMID:20012394; http://dx.doi.org/10.1007/ 978-1-60761-058-8-6
21. Stein C, Kling L, Proetzel G, Roopenian DC, De Angelis MH, Wolf E, Rathkolb B. Clinical chemistry of human FcRn transgenic mice. Mamm Genome 2012; 23:259-69; PMID:22193411; http://dx.doi.org/ 10.1007/s00335-011-9379-6
22. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601
23. Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. mAbs 2013; 5:397-405; PMID:23549129; http://dx. doi.org/10.4161/mabs.23836
24. Gaj T, Gersbach CA, Barbas Iii CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013; PMID:23664777
25. Nishio H, Dugaiczyk A. Complete structure of the human a-albumin gene, a new member of the serum albumin multigene family. Proc Natl Acad Sci U S A 1996; 93:7557-61; PMID:8755513; http://dx.doi.org/ 10.1073/pnas.93.15.7557
26. Baldo-Enzi G, Baiocchi MR, Vigna G, Andrian C, Mosconi C, Fellin R. Albuminaemia: A natural model of metabolic compensatory systems. J Inherit Metab Dis 1987; 10:317-29; PMID:3126352; http://dx.doi. org/10.1007/BF01799973
27. Prinsen BHCMT, Kaysen GA, Klomp LWJ, De Boer J, Barrett PHR, Thornalley PJ, Battah S, Berger R, Rabelink TJ, De Sain-van der Velden MGM. Idiopathic hypoalbuminemia explained by reduced synthesis rate and an increased catabolic rate. Clin Biochem 2002; 35:545-53; PMID:12493583; http://dx.doi.org/ 10.1016/S0009-9120(02)00357-0
28. Kallee E. Bennhold's analbuminemia: A follow-up study of the first two cases (1953-1992). J Lab Clin Med 1996; 127:470-80; PMID:8621984; http://dx. doi.org/10.1016/S0022-2143(96)90064-5
29. Koot BGP, Houwen R, Pot DJ, Nauta J. Congenital analbuminaemia: Biochemical and clinical implications. A case report and literature review. Eur J Pediatr 2004; 163:664-70; PMID:15300429
30. Caridi G, Dagnino M, Erdeve O, Di Duca M, Yildiz D, Alan S, Atasay B, Arsan S, Campagnoli M, Galliano M, et al. Congenital analbuminemia caused by a novel aberrant splicing in the albumin gene. Biochem Med 2014; 24:151-8; PMID:24627724; http://dx.doi.org/ 10.11613/BM.2014.017
31. Braschi S, Lagrost L, Florentin E, Martin C, Athias A, Gambert P, Krempf M, Lallemant C, Jacotot B. Increased cholesteryl ester transfer activity in plasma from analbuminemic patients. Arterioscler Thromb Vasc Biol 1996; 16:441-9; PMID:8630671; http://dx. doi.org/10.1161/01.ATV.16.3.441
32. Maugeais C, Braschi S, Ouguerram K, Maugeais P, Mahot P, Jacotot B, Darmaun D, Magot T, Krempf M. Lipoprotein kinetics in patients with analbuminemia: Evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler Thromb Vasc Biol 1997; 17:1369-75; PMID:9261269; http://dx.doi. org/10.1161/01.ATV.17.7.1369
33. Minchiotti L, Galliano M, Caridi G, Kragh-Hansen U, Peters T Jr. Congenital analbuminaemia: Molecular defects and biochemical and clinical aspects. Biochim Biophys Acta 2013; 1830:5494-502; http://dx.doi.org/ 10.1016/j.bbagen.2013.04.019
34. Ando S, Kon K, Tanaka Y, Nagase S, Nagai Y. Characterization of hyperlipidemia in Nagase analbuminemia rat (NAR). J Biochem 1980; 87:1859-62; PMID:7400127
35. Nagase S, Shimamune K, Shumiya S. Albumin-deficient rat mutant: An animal model for analbuminemia. Jikken Dobutsu 1980; 29:33-8; PMID:7398800
36. Dammacco F, Miglietta A, Bonomo L. Analbuminemia - A quantitative albumin variant. Ric Clin Lab 1979; 9:5-12; PMID:115079
37. Adachi Y, Kambe A, Yamashita M, Inufusa H, Nagase S, Yamamoto T. Serum bilirubin fractions in analbuminemic rats after bile duct ligation. Albumin requirement in the formation of covalently protein-bound bilirubin. J Hepatol 1988; 7:224-8; PMID:3192924; http://dx.doi.org/10.1016/S0168-8278(88)80486-0
38. Trull A, Hughes V, Cooper D, Wilkins M, Gimson A, Friend P, Johnston A, Sharples L, Park G. Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. Liver Transpl 2002; 8:224-32; PMID:11910567; http://dx. doi.org/10.1053/jlts.2002.31347
39. Reyon D, Khayter C, Regan MR, Joung JK, Sander JD. Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly. Curr Protoc Mol Biol 2012; UNIT 12.15; PMID:23026907.
40. Reyon D, Tsai SQ, Khgayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for highthroughput genome editing. Nat Biotechnol 2012; 30:460-5; PMID:22484455; http://dx.doi.org/ 10.1038/nbt.2170
41. Branten AJW, Swinkels DW, Klasen IS, Wetzels JFM. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol Dial Transplant 2004; 19:2754-60; http://dx.doi.org/10.1093/ ndt/gfh454
42. Whayne TF Jr, Felts JM. The determination of lipoprotein lipase activity: Effect of different albumin preparations. Clin Biochem 1972; 5:109-14; PMID:5039592; http://dx.doi.org/10.1016/S0009-9120(72)80017-1